Gossamer Bio, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Patrick Trucchio has given his Buy rating due to a combination of factors related to Gossamer Bio’s progress with its seralutinib programs. The company is advancing steadily with its late-stage trials for seralutinib in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Phase 3 trial for PAH, known as PROSERA, is on track for a pivotal readout in February 2026, which is seen as a significant value inflection point for the company.
Additionally, the initiation of the SERANATA trial in PH-ILD marks the expansion of seralutinib into a second registrational program. The trials are designed to demonstrate seralutinib’s potential as a best-in-class therapy, with promising data from earlier studies supporting its efficacy. These developments, combined with the potential for seralutinib to modify disease progression beyond just vasodilation, underpin Trucchio’s confidence in Gossamer Bio’s future prospects, justifying the Buy rating and a price target of $10 per share.
In another report released on November 10, Oppenheimer also maintained a Buy rating on the stock with a $12.00 price target.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GOSS in relation to earlier this year.